Clear Scientific Attends 2026 Coastal Emergency Medicine Conference (CEMC)

Kiawah Island, SC | June 2026

Peter Howe, CFO, and Shekar Shetty, CEO, from Clear Scientific attended the 2026 Coastal Emergency Medicine Conference (CEMC) June 4^th-6^th in Kiawah Island, South Carolina.

For over a decade, this American College of Emergency Physician (ACEP) chapter has hosted Emergency Physicians from Georgia, South Carolina and North Carolina as well as associated professionals to connect, share practice-changing education, and engage in forward-thinking collaboration.   

Through conversations with physicians at CEMC, it was clear that methamphetamine intoxication is a significant problem across the southeast region of the U.S. Multiple clinicians reported seeing 3 or more methamphetamine-related admissions per day.  These situations often put patients, first responders, emergency clinicians, and staff at risk, while also disrupting care for others, further staining already limited EMS and ED resources.  

Meth cases often require chemical or physical restraint followed by prolonged sedation and monitoring, with bed occupancy ranging from 12 to 72 hours.  Many of these patients are admitted to the psychiatric unit for further evaluation; it is often difficult to distinguish between substance-induced psychosis and an underlying mental health condition. Poly-substance intoxication is also extremely common, further complicating diagnosis and treatment.   

With no approved standard of care to reverse methamphetamine or poly-substance intoxication, treatment often relies on sedation, e.g. benzodiazepines, ketamine or anti-psychotics highlighting the significant unmet medical need.  

About Clear Scientific: 

Clear Scientific was co-founded in March 2019 by Professor George M. Whitesides of Harvard University with technology licensed from Massachusetts General Hospital and the University of Maryland.  

Clear Scientific is pioneering a new paradigm for treatment of conditions and diseases that involve an excess of specific compounds in the body. The company is developing highly selective, small molecule sequestrants that bind, inactivate, and rapidly clear these excess compounds from the body. Clear Scientific receives funding from the National Institutes of Health (NIH) / National Institute on Drug Abuse (NIDA) and is working with their network of medical and academic professionals.  

About CS-1103: 

CS-1103 is a first-in-class injectable small molecule sequestrant that binds and inactivates target compounds, rapidly reversing their effects and accelerating their clearance into urine. Clear Scientific is initially targeting methamphetamine, fentanyl and cocaine overdose, representing close to 95% of drug fatalities in the US. The Company’s pipeline includes indications in substance use disorder, central nervous system (CNS) and metabolic diseases amongst others. CS-1103 is investigational and has not been approved by any health authority.

For more information, visit https://www.clearsci.com